GlobalData on MSN

Tandem secures FDA approval for Control-IQ+ use in pregnancy

The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.
Healio

FDA clears first automated insulin delivery system for type 1 diabetes during pregnancy

The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...
Business Wire

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
Business Wire

Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with U-100 insulin only. WARNING: Control-IQ technology should not be used by anyone under the age ...
EurekAlert!

A meta-analysis of hybrid-closed loop control-IQ technology

A new study evaluated the effect of hybrid-closed loop Control-IQ technology in the pooled data from three randomized controlled trials, comparing Control-IQ to a control group using continuous ...